Product Name	:	Defactinib
Synonyms	:	VS-6063;VS6063;PF04554878;PF-04554878
Cat No.	:	M10299
CAS Number	:	1073154-85-4
Molecular Formula	:	C20H21F3N8O3S
Formula Weight	:	510.49
Chemical Name	:	Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-
Description	:	Defactinib (VS-6063, PF-04554878) is a potent, selective and orally active FAK inhibitor, selectively inhibits pFAK (Tyr397) in a dose-dependent manner in cancer cell lines; shows no statistically significant changes in FAK phosphorylation at the other residues(Tyr 576/577, Tyr 925, or Tyr 861), also inhibits Pyk2 Tyr402 phosphorylation in HeyA8 cells; markedly decreases proliferation and increases apoptosis combined with paclitaxel, reduces levels of AKT and YB-1 in taxane-resistant cell lines; significantly reduces tumor growth, synergized with the mTOR inhibitor everolimus in xenograft models of pancreatic tumor.Lung Cancer Phase 2 Clinical
Pathway	:	Angiogenesis
Target	:	FAK
Receptor	:	FAK
Solubility	:	DMSO: ≥ 39 mg/mL
SMILES	:	CNC(=O)C1=CC=C(NC2=NC=C(C(NCC3=NC=CN=C3N(C)S(C)(=O)=O)=N2)C(F)(F)F)C=C1
Storage	:	(-20℃)
Stability	:	≥ 2 years
Reference	:	



1. Kang Y, et al. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.| 2. Shimizu T, et al. Cancer Chemother Pharmacol. 2016 May;77(5):997-1003.| 3. Jones SF, et al. Invest New Drugs. 2015 Oct;33(5):1100-7.| 4. Franois RA, et al. J Natl Cancer Inst. 2015 May 12;107(8). pii: djv123.